The Value of Inflammatory Biomarkers in Differentiating Asthma–COPD Overlap from COPD

Abstract

Purpose

To evaluate the accuracy of inflammatory biomarkers in differentiating patients with asthma–COPD overlap (ACO) from those with COPD alone.

Methods

Clinical data of 134 patients with COPD and 48 patients with ACO admitted to the First Affiliated Hospital of Xi’an Jiaotong University from January 2016 to June 2019 were retrospectively analyzed. Receiver operating characteristic (ROC) curve analysis was performed to determine the best cut-off values of fractional exhaled nitric oxide (FeNO), blood eosinophil counts (EOS), and neutrophil to lymphocyte ratio (NLR) for differentiating between ACO and COPD alone. Spearman correlation analysis was conducted to evaluate the relationships between these inflammatory biomarkers and the forced expiratory volume in one second/prediction (FEV₁%pred).

Results

FeNO and EOS in the ACO patients were significantly higher than those in the COPD patients (FeNO: median 37.50 vs 24.50 ppb, P < 0.001; EOS: median 0.20 vs 0.10 ×10⁹/L, P = 0.004). FeNO was positively correlated with FEV₁%pred (r = 0.314, P = 0.030), while NLR was negatively correlated with FEV₁%pred (r = −0.372, P = 0.009) in patients with ACO. In addition, a positive correlation between FeNO and EOS was also found in ACO, especially in patients without history of inhaled corticosteroids (ICS) use (r = 0.682, P < 0.001). The optimal cut-off value of FeNO was 31.5 ppb (AUC = 0.758, 95% CI = 0.631–0.886) in patients with smoking history, with 70.0% sensitivity and 89.9% specificity for differentiating ACO from COPD. In patients without history of ICS use, the best cut-off value of FeNO was 39.5 ppb (AUC = 0.740, 95% CI = 0.610–0.870), with 58.3% sensitivity and 84.9% specificity. Among patients without history of ICS use and smoking, 27.5 ppb was optimal cut-off level for FeNO (AUC = 0.744, 95% CI = 0.579–0.908) to diagnose ACO, with 81.8% sensitivity and 60.7% specificity, and the sensitivity was improved to 91.7% when FeNO was combined with EOS.

Conclusion

The inflammatory biomarkers FeNO and EOS can be used as indicators for differentiating between ACO and COPD alone.

Keywords:

• fractional exhaled nitric oxide
• blood eosinophil counts
• neutrophil to lymphocyte ratio
• chronic obstructive pulmonary disease
• asthma–COPD overlap

Introduction

Asthma–COPD overlap (ACO) is characterized by persistent airflow limitation with several features usually associated with both asthma and COPD.¹ It has been reported that ACO has a prevalence of 15–20% among patients with COPD,^2,3 the incidence increases in an age-dependent manner, with a prevalence of about 23% in patients aged 50–59 years but 52% in those over 70 years.⁴ The last Global Initiative for Chronic Obstructive Lung Disease (GOLD) update suggests that the patient should be treated accordingly when asthma is suspected.⁵ However, sometimes this is hard to be performed since several smokers have reversibility and increased sputum eosinophils making the recognition of the asthma component in a COPD patient difficult.⁵ By now, there are no unified standards to differentiate ACO from COPD alone. The stepwise approach for the diagnosis of ACO, proposed jointly by Global Initiative for Asthma (GINA) and GOLD, are mainly based on symptoms but lack objective indicators such as imaging characteristics and inflammatory biomarkers.¹ The diagnostic procedure based on this criteria is also complicated for clinical application, especially to outpatients. Therefore, it is of great practical significance to find new objective indicators for recognizing the asthma component in COPD and diagnosing ACO.

Fractional exhaled nitric oxide (FeNO), blood eosinophil counts (EOS), and neutrophil to lymphocyte ratio (NLR), as indicators of airway or systemic inflammation, have been used to improve the accuracy in diagnosing asthma, guide asthma interventions, monitor the response to inhaled corticosteroids (ICS) treatment, evaluate eosinophilic airway inflammation, and assess the risk of acute exacerbation of COPD (AECOPD).^6–12 FeNO and EOS were suggested by the GINA/GOLD joint document and Spanish ACOS Diagnostic Consensus 2017 to be used as inflammatory biomarkers to differentiate ACO from COPD.^1,13 Neutrophils and NLR, as indicators of circulating immune complexes, were found remarkably higher in patients with airflow limitation (including COPD and ACO) than those in the healthy population,¹⁴ which suggested that NLR may be used as a biomarker to distinguish and diagnose different types of obstructive diseases.

Although some relevant studies have proved that FeNO and EOS are useful indicators to a certain extent in distinguishing ACO from COPD,^15–20 the value of these inflammatory biomarkers in ACO diagnosis remains contradictory and inconclusive. In addition, most studies included patients with a history of smoking or ICS use,^15–20 which might affect the expressions of the inflammatory biomarkers.^21–24 What’s more, there is no research on the NLR in distinguishing between COPD and ACO. To address these problems, the present retrospective study was performed to further evaluate the accuracy of FeNO, EOS, and NLR for the clinical diagnosis of ACO after eliminating the influence of confounding factors.

Patients and Methods

Patients and Ethics Statement

The present study recruited 134 patients with COPD alone and 48 patients with ACO. All subjects with COPD were defined as a post-bronchodilator with a forced expiratory volume in 1 second/forced vital capacity ratio (FEV₁/FVC) less than 0.70 with at least one of the following appropriate symptoms: cough, expectoration, wheezing and significant exposures to noxious stimuli (tobacco, occupation, indoor and outdoor air pollution).⁵ Asthma should be excluded from all patients with COPD alone. The definition of asthma according to GINA diagnostic criteria,¹ patients fulfilled a history of various respiratory symptoms, such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, and determination of variable expiratory flow limitations (increased in FEV₁≥200 mL and ≥12% from baseline after the use of a bronchodilator or 4 weeks after the anti-inflammatory treatment, outside respiratory infections).

ACO patients were confirmed according to the universally accepted definition of the GINA/GOLD joint document.¹ The characteristics that suggest the diagnosis of asthma and COPD (including the following general categories: age at onset, pattern of symptoms, lung function, patient or family history, time course, and chest X-ray) were listed in Supplementary Table 1.¹ Patients who satisfied the 3 or more characteristics of asthma or COPD can be diagnosed accordingly. If the number of characteristics of asthma and COPD are similar, ACO can be diagnosed. In addition, the following conditions must be also satisfied for ACO patients in this study: (1) age ≥ 40; (2) a history of chronic cough, phlegm and exertion dyspnea; (3) evidence of persistent airflow limitation (FEV₁/FVC < 0.7 after bronchodilator); (4) a past history of asthma or strong evidence of reversible airflow limitation (increase in FEV₁≥400mL and ≥15% from baseline after inhaling bronchodilator). Exclusion criteria were as follows: (1) diagnosis of bronchiectasis, interstitial lung disease, lung cancer, or tuberculosis; (2) suffering from other diseases affecting levels of inflammatory markers, such as severe autoimmune diseases, hematologic disease and metabolic diseases; (3) having received oral or intravenous glucocorticoid therapy in the preceding 4 weeks; (4) history of severe liver and kidney dysfunction or malignant tumor; (5) incomplete clinical data of patients. These diagnostic features were evaluated and extracted from the Electronic Medical Record System (EMRS). The study was approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University, and written informed consents from patients were waived because it was a non-interventional retrospective study. We confirmed that the data of patients was maintained with confidentiality.

Methods

Pulmonary Function Test

Pulmonary function and bronchial dilation tests were performed using the pulmonary function equipment (MSD+APS, Germany). The tests were performed by professional medical technicians and repeated twice to obtain the best results.

FeNO Measurement

FeNO level were measured by using the Sunvou device (Sunvou Medical Electronics Co. LTD, Wuxi, CHN) with the method recommended by the American Thoracic Society/European Respiratory Society (ATS/ERS) Committee.²⁵ The patient sat or stood straight, placed the filter in their mouth, and exhaled at a steady rate of 50 mL/s for 6–10 seconds immediately after deep inhalation, during which aeration and breath-holding were prohibited. For the test, patients had to satisfy the following conditions: no strenuous exercise, smoking and feeding one hour before the test; no broccoli, lettuce, celery and smoked or pickled foods three hours before the test; no history of respiratory infection or antibiotic use within one week before the test; no history of oral or intravenous glucocorticoids use within four weeks before the test. The results of FeNO were represented as parts per billion (ppb). FeNO level was classified as follows: normal, <25 ppb, non-eosinophilic airway inflammation; intermediate, 25–50 ppb, mixed airway inflammation; and high, >50 ppb, eosinophilic airway inflammation.

EOS and NLR Measurement

EOS and NLR were determined from peripheral blood samples. EOS levels were reported as ×10⁹/L. Other clinical data were extracted from the EMRS. All of the pulmonary function test, FeNO, and blood test were performed on the same day.

Statistical Analysis

Statistical analysis were performed using SPSS 18.0 (SPSS Inc, Chicago, IL), PASS 11 (NCSS, LLC. Kaysville, Utah, USA) and Microsoft Excel (Microsoft Corp., Redmond, WA). Percentage was used to express the enumeration data. Measurement data were shown as median (interquartile range) or mean ± standard deviation, unless otherwise specified. Chi-square test and t-test were used to compare the distribution of categorical and continuous variables between the two groups, respectively. Mann–Whitney U-test was used to compare the non-normally distributed data between groups. Spearman’s rank correlation coefficient was used to assess the relationship between FeNO and EOS and the correlation between the biomarkers and FEV₁%pred. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of inflammatory biomarkers in differentiating ACO from COPD. P<0.05 was considered as statistically significant.

Results

Baseline Characteristics of the Patients

This study enrolled a total of 182 participants, including 134 patients with COPD alone (91 males and 43 females; average age: 67.66±8.63 years) and 48 patients with ACO (26 males and 22 females; average age: 61.13±9.41 years), which met the requirements of sample size calculated before our study (at least 41 patients of ACO and COPD, respectively). The proportion of patients with a history of smoking was lower in the ACO group than in the COPD group (41.7% vs 59.0%, P = 0.044). The ACO patients were comparatively younger (61.13±9.41 years vs 67.66±8.63 years, P < 0.001) and had a lower FEV₁/FVC level (50.66±8.22% vs 52.35±10.63%, P = 0.009). Detailed characteristics of the study patients are listed in Table 1.

Table 1 Characteristics of the Study Patients (n=182)

Characteristics	COPD (n = 134)	ACO (n = 48)	P-value
Sex (M/F)	91/43	26/22	0.114
Age (years)	67.66±8.63	61.13±9.41	<0.001*
BMI (kg/m^2)	22.57±3.24	23.03±3.47	0.703
Smoking history	79 (59.0%)	20 (41.7%)	0.044*
Smoking status
Current smoking	48(25.8%)	8(40.0%)	0.094
Ex-Smoking	31(74.2%)	12(60.0%)
ICS use	61 (45.5%)	24 (50.0%)	0.617
Comorbidity
Hypertension	47 (35.1%)	13 (27.1%)	0.373
Diabetes mellitus	10 (7.5%)	3 (6.3%)	0.998
Cardiovascular disease	25 (18.7%)	3 (6.3%)	0.060
Neutrophils (10^9/L)	4.80 (3.60, 7.06)	4.55 (3.28, 6.47)	0.426
Lymphocyte (10^9/L)	1.33 (0.97, 1.70)	1.47 (1.03, 1.89)	0.432
Platelet (10^9/L)	192.00 (170.00, 236.00)	211.50 (181.25, 301.5)	0.028*
EOS (10^9/L)	0.10 (0.04, 0.21)	0.20 (0.07, 0.45)	0.004*
NLR	3.99 (2.31, 6.12)	3.27 (2.16, 4.59)	0.287
PLR	148.35 (112.54, 206.23)	142.67 (118.43, 251.62)	0.563
CRP (mg/L)	5.20 (3.10, 20.85)	5.21 (3.20, 17.23)	0.804
FVC (L)	2.06 (1.52,2.69)	2.00 (1.51, 2.41)	0.356
FEV1(L)	1.03 (0.78, 1.30)	1.12 (0.79, 1.41)	0.382
FEV1/FVC (%)	52.35±10.63	50.66±8.22	0.009*
FEV1%pred (%)	38.00 (29.00, 52.00)	39.00 (32.25, 52.25)	0.484
FeNO (ppb)	24.50 (16.75, 33.50)	37.50 (23.00, 60.75)	<0.001*

Notes: Data are shown as number (%) or medians (interquartile range) or means±SD, *P<0.05 value indicates statistical significance.

Abbreviations: COPD, chronic obstructive pulmonary disease; ACO, asthma–COPD overlap; BMI, body mass index; ICS, inhaled corticosteroids; EOS, blood eosinophils count; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, c-reactive protein; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; FEV₁%pred, forced expiratory volume in one second/prediction; FeNO, fractional exhaled nitric oxide.

Levels of FeNO, EOS, and NLR in the Patients

The levels of FeNO and EOS were significantly higher in patients with ACO than in patients with COPD alone [FeNO: median 37.50 (23.00, 60.75) ppb vs 24.50 (16.75, 33.50) ppb, P < 0.001; EOS: median 0.20 (0.07, 0.45)×10⁹/L vs 0.10 (0.04, 0.21)×10⁹/L, P = 0.004; Table 1, Figure 1A and B]. The differences also existed in patients who had never used ICS (FeNO: P < 0.001; EOS: P = 0.005; Figure 1A and B), and patients with a history of smoking (FeNO: P < 0.001; EOS: P = 0.008; Figure 1A and B). In addition, among patients with no history of both ICS use and smoking, only FeNO showed a significant difference between the two groups (P = 0.019; Figure 1A). No significant FeNO and EOS between-group differences were found among patients with a history of ICS use and smoking simultaneously (Figure 1A and B). The level of NLR did not show a difference between COPD and ACO in all conditions (Figure 1C).

Figure 1 Inflammatory biomarkers levels in COPD and ACO.

Notes: (A) FeNO levels; (B) EOS levels; (C) NLR levels. All of them are shown as medians (interquartile range). Mann–Whitney U-test were used to assess the differences between groups. P<0.05 indicates statistical significance.

Abbreviations: FeNO, fractional exhaled nitric oxide; EOS, blood eosinophils count; NLR, neutrophil to lymphocyte ratio; ICS, inhaled corticosteroids.

Correlation Analysis of FeNO and EOS in ACO Patients

FeNO and EOS were positively correlated in ACO patients (r = 0.497, P < 0.001; Figure 2A), especially in patients that had never used ICS (r = 0.682, P < 0.001; Figure 2B) and patients with a smoking history (r = 0.643, P = 0.002; Figure 2E). Of patients with a history of ICS use and patients without a history of smoking, no correlation of the two markers was found in ACO patients (Figure 2C and D).

Figure 2 Correlation of FeNO with EOS in patients with ACO.

Notes: (A) overall patients; (B) patients without ICS use; (C) patients with ICS use; (D) patients without smoking history; (E) patients with smoking history. P<0.05 indicates statistical significance.

Abbreviations: FeNO, fractional exhaled nitric oxide; EOS, blood eosinophils count; NLR, neutrophil to lymphocyte ratio; ICS, inhaled corticosteroids.

Correlation Analysis of FeNO, EOS and NLR with FEV₁%pred in ACO Patients

Correlation analysis showed that FeNO and NLR were positively and negatively correlated with FEV₁%pred in patients with ACO, respectively (FeNO: r = 0.314, P = 0.030; NLR: r = −0.372, P = 0.009; Figure 3A and C). No relationship between EOS and FEV₁%pred was found in this study (Figure 3B).

Figure 3 Correlation of inflammatory biomarkers with FEV₁%pred in patients with ACO.

Notes: (A) FeNO with FEV₁%pred; (B) EOS with FEV₁%pred; (C) NLR with FEV₁%pred; P<0.05 indicates statistical significance.

Abbreviations: FeNO, fractional exhaled nitric oxide; EOS, blood eosinophils count; NLR, neutrophil to lymphocyte ratio.

Diagnostic Accuracy of FeNO, EOS, and NLR in Identifying ACO and COPD

ROC curve analysis showed that 39.5 ppb was the best cut-off value of FeNO in identifying ACO and COPD in the entire cohort of patients [AUC = 0.683, 95% confidence interval (CI) = 0.590–0.776], with a sensitivity of 50.0% and a specificity of 83.6% (Table 2, Figure 4A). Among patients without ICS use, the optimal cut-off level was 39.5 ppb (AUC = 0.740, 95% CI = 0.610–0.870), with 58.3% sensitivity and 84.9% specificity (Table 2, Figure 4B). In addition, the optimal cut-off value of FeNO was 31.5 ppb (AUC = 0.758, 95% CI = 0.631–0.886) in patients with a smoking history, and the corresponding sensitivity was 70.0% and the specificity was 89.9% (Table 2, Figure 4D). As for EOS, 0.335×10⁹/L was found to be the best cut-off value for ACO diagnosis in overall patients, with 39.6% sensitivity and 90.3% specificity (AUC = 0.640, 95% CI = 0.542–0.738; Table 2, Figure 4A). In patients with no ICS use and patients with a smoking history, the AUC of EOS increased but was still relatively low (Table 2, Figure 4B and D). It’s worth noting that only FeNO can be used to distinguish the two diseases after excluding the effect of both ICS use and smoking history at the same time, and the best cut off value was 27.5 ppb (AUC = 0.744, 95% CI = 0.579–0.908), with 81.8% sensitivity and 60.7% specificity (Table 2, Figure 4F). However, among patients with ICS treatment, patients with no smoking history, and patients with ICS treatment and smoking history simultaneously, FeNO and EOS showed no diagnostic value in distinguishing ACO from COPD (Table 2, Figure 4C, E and G). In short, both EOS and FeNO had high specificity in distinguishing ACO from COPD, and FeNO showed a higher diagnostic sensitivity in patients without ICS treatment and smoking history. NLR did not show a notable value in differentiating ACO from COPD (Figure 4A–G).

Table 2 Diagnostic Accuracy of Inflammatory Biomarkers

Biomarkers	AUC (95% CI)	Sen. (%)	Spe. (%)	PPV (%)	NPV (%)	P-value
Overall (n = 182)
FeNO≥39.5 ppb	0.683 (0.590–0.776)	50.0	83.6	52.2	82.4	<0.001*
EOS≥0.335×10^9/L	0.640 (0.542–0.738)	39.6	90.3	59.4	80.7	0.004*
FeNO + EOS	0.678 (0.580–0.775)	69.8	75.5	53.6	82.5	<0.001*
No ICS use history (n = 97)
FeNO≥39.5ppb	0.740 (0.610–0.870)	58.3	84.9	56.0	86.1	<0.001*
EOS≥0.285×10^9/L	0.693 (0.554–0.833)	41.7	94.5	71.4	83.1	0.005*
FeNO + EOS	0.740 (0.610–0.869)	75.7	80.2	56.3	90.7	<0.001*
ICS use history (n = 85)
FeNO≥40.5ppb	0.635 (0.506–0.765)	41.7	82.0	47.6	78.1	0.053
EOS≥0.335×10^9/L	0.588 (0.449–0.727)	41.7	80.3	45.5	77.8	0.208
FeNO + EOS	0.623 (0.482–0.764)	66.0	65.9	44.4	83.7	0.078
No smoking history (n = 83)
FeNO≥39.5ppb	0.632 (0.502–0.761)	46.4	80.0	22.8	42.3	0.051
EOS≥ 0.335×10^9/L	0.617 (0.479–0.755)	35.7	92.7	16.4	81.8	0.084
FeNO + EOS	0.638 (0.506–0.769)	65.5	74.2	56.3	80.4	0.050
Smoking history (n = 99)
FeNO≥31.5ppb	0.758 (0.631–0.886)	70.0	89.9	40.0	90.6	<0.001*
EOS≥0.360×10^9/L	0.692 (0.556–0.828)	45.0	73.4	52.9	86.6	0.008*
FeNO + EOS	0.742 (0.600–0.885)	83.5	66.0	38.6	94.6	<0.001*
No ICS use and smoking history (n = 39)
FeNO≥27.5ppb	0.744(0.579,0.908)	81.8	60.7	45.0	89.5	0.019*
EOS≥0.305×10^9/L	0.597(0.367,0.828)	54.5	71.4	42.9	80.0	0.349
FeNO + EOS	0.727(0.560,0.894)	91.7	43.3	38.5	92.3	0.029*
Both ICS use and smoking history (n = 41)
FeNO≥40.5pb	0.574(0.338,0.809)	42.9	79.4	30.0	87.1	0.782
EOS≥0.660×10^9/L	0.534(0.292,0.775)	28.6	94.1	50.0	86.5	0.544
FeNO + EOS	0.534(0.281,0.786)	59.2	74.7	30.8	89.3	0.782

Note: *P<0.05 value indicates statistical significance.

Abbreviations: AUC, area under curve; 95% CI, 95% confidence interval; Sen, sensitivity; Spe, specificity; PPV, positive predictive value; NPV, negative predictive value; ICS, inhaled corticosteroids; EOS, blood eosinophils count; FeNO, fractional exhaled nitric oxide.

Figure 4 ROC curve for inflammatory markers for differentiating ACO from COPD.

Notes: (A) overall patients; (B) patients without ICS use; (C) patients with ICS use; (D) patients with smoking history; (E) patients without smoking history; (F) patients without smoking and ICS use history; (G) patients with smoking and ICS use history.

Abbreviations: FeNO, fractional exhaled nitric oxide; EOS, blood eosinophils count; NLR, neutrophil to lymphocyte ratio; ICS, inhaled corticosteroids.

Diagnostic Accuracy of FeNO and EOS in Combination

Given the low sensitivity of either FeNO or EOS in distinguishing ACO from COPD, further analysis was conducted to explore the diagnostic value of the two inflammatory biomarkers in combination. The multi-index combined ROC curve showed that the AUC of the combined indexes was larger than that of EOS alone (Figure 4). In addition, the value of the combined indexes was also further calculated, in which ACO was confirmed as long as either index was above the cut-off value. As shown in Table 2 and Figure 4A, combination of FeNO≥39.5 ppb and EOS≥0.335×10⁹/L had 69.8% sensitivity and 75.5% specificity in overall patients (AUC = 0.678, 95% CI = 0.580–0.775). Among patients not having used ICS, 75.7% sensitivity and 80.2% specificity were achieved under the combination of FeNO≥39.5ppb and EOS≥0.285×10⁹/L (AUC = 0.740, 95% CI = 0.610–0.869; Table 2, Figure 4B). 83.5% sensitivity and 66.0% specificity were identified under the combination of FeNO≥31.5ppb and EOS≥0.360×10⁹/L among patients with a smoking history (AUC = 0.742, 95% CI = 0.600–0.885; Table 2, Figure 4D). What’s more, in patients without a history of both ICS use and smoking, 91.7% sensitivity and 43.3% specificity were achieved (AUC = 0.727, 95% CI = 0.560–0.894; Table 2, Figure 4F) when the two biomarkers combined. These results confirmed that the combination of FeNO and EOS can improve the sensitivity of ACO diagnosis, but reduce the specificity to some extent.

Discussion

Up to now, the clinical management of ACO has remained difficult due to the lack of precise definition and unified diagnostic criteria. As multiple phenotypes have been verified in ACO,^26,27 there is an increased awareness of the importance and clinical significance in the diagnosis, treatment, prognosis, and recurrence of ACO by monitoring the level of inflammation. Compared to the induced sputum method recommended in previous guidelines,²⁸ inflammatory biomarkers FeNO, EOS and NLR are more rapid, convenient, reproducible, and less painful. However, all of them are affected by factors such as therapeutic drugs and smoking.^21–24 Therefore, the present study was conducted to further evaluate the accuracy of FeNO, EOS, and NLR in ACO diagnosis after excluding the influence of ICS and smoking use.

Congruent with some previous studies,^15–20 our results confirmed the higher levels of FeNO and EOS in ACO patients than in COPD patients, especially in those without ICS use or with a smoking history. A possible reason for the results may be that chronic airway inflammation in asthma and COPD is mainly characterized by eosinophils and neutrophils, respectively,^1,5 and ACO shares the airway inflammation characteristics of both COPD and asthma.¹ In addition, FeNO has been used as an alternative indicator for eosinophilic airway inflammation and is a useful tool for diagnosing and monitoring asthma.^6,7 What’s more, steroid responsiveness, airway inflammation, and airway remodeling that occur in asthma and COPD are associated with cigarette smoking.²⁴ Patients with asthma who smoke have larger numbers of neutrophils and eosinophils.^24,29,30 Therefore, the FeNO and EOS levels were higher in the ACO patients, and increased FeNO and EOS levels in ACO patients also manifest that ACO has an eosinophil airway inflammatory response similar to asthma. Unlike previous studies,^29,31 we found that the FeNO level increased in patients with a smoking history. It may be due to the existence of some other factors that affect the level of FeNO, such as a nitrate rich diet before examination and contamination of nasal exhaled nitric oxide (nNO). In addition, Rouhos et al²³ demonstrated that smoking seems to attenuate the increase in FeNO in atopic but not in nonatopic asthmatics. This may be due to the reason that some ACO patients in this study showed characteristics of nonatopic asthmatics. It’s worth noting that although 41.0% (55/134) of COPD and 58.3% (28/48) of ACO patients in this study had no smoking history, all of them were chronically exposed to high levels of fine particulate air pollution or biomass for cooking or heating, which is the main causes of COPD and ACO. Consistent with previous studies,^3,15,32 the ACO patients in our study were younger than those with COPD, and they had poorer lung functions. Several researches confirmed that ACO patients tend to have more severe symptoms, faster deterioration and higher mortality rates compared to asthma and COPD alone,^33–35 and most patients seek medical treatment earlier for these above reasons, which may increase the early detection of the disease.

Several studies revealed a weak-to-moderate correlation between eosinophils in sputum and FeNO in patients with asthma,^36,37 while Takayama et al¹⁸ claimed that the correlation between FeNO and EOS was insignificant in patients with either ACO or COPD. This might be because FeNO and EOS are involved in two different inflammatory pathways, namely, the interleukin-4 (IL-4) and IL-13-mediated pathway³⁸ and the IL-5-mediated pathway.³⁹ Different from these studies, our results showed a moderate correlation between FeNO and EOS in patients with ACO, especially in patient without ICS use and patients with a smoking history. Prado et al⁴⁰ confirm that neurokinins and nitric oxide (NO) are involved in iNOS-negative eosinophil and iNOS-positive eosinophil recruitment, respectively. NO may promote eosinophil and mononuclear cell response in the distal airways. Gao et al³⁷ identified a significant positive correlation between FeNO and sputum eosinophils, and Hartjes et al⁴¹ detected a tight association of higher eosinophils levels in blood with higher eosinophils levels in sputum. These findings, together with ours, suggested that FeNO and EOS may interact in a certain inflammatory pathway, and combination of the two biomarkers may increase the diagnostic sensitivity for the ACO. Whereas, further analysis revealed that the association between FeNO and EOS disappeared in patients with the experience of ICS treatment. This may be attributed to the reduced expression of inflammatory biomarkers when using ICS.^21,22

Shi et al⁴² confirmed that FeNO was negatively associated with FEV₁%pred in COPD and ACO. However, Liu et al⁴³ demonstrated a higher proportion of patients with GOLD III–IV and more exacerbations in patients with low FeNO levels. Vedel-krogh et al¹⁰ found that FEV₁%pred was slightly lower in individuals with a high EOS level in patients with COPD, while higher FEV₁%pred was found in patients with a high EOS level in the ECLIPSE study.⁴⁴ Furutate et al¹² found inversely correlation between NLR and FEV₁ in COPD patients. Up to now, the correlation among EOS, NLR and FEV₁%pred in ACO patients has not been systematically explored. Similar to the previous researches,^43,45 our study revealed that FeNO was positively correlated with FEV1%pred in patients with ACO. Although previous studies have found that increased neuronal nitric oxide synthase (nNOS) in patients with severe COPD and promote the production of FeNO,⁴⁶ these patients with exacerbation and poor lung function may use more ICS to relieve dyspnea symptoms, which reduced the concentrations of FeNO. So its clinical relevance still remains controversial and needs to be confirmed in other studies. In addition, our study also found a negative relation between NLR and FEV1%pred in patients with ACO. AECOPD is generally thought to be significantly associated with infection,⁴⁷ previous studies have manifested that infectious AECOPD is characterized by an increased level of NLR, which may be caused by pathogens inducing a stronger inflammatory response mediated by neutrophils rather than lymphocyte.^48,49 Neutrophils have been shown to influence the pulmonary ventilation function by participating in the inflammatory response and remodeling in the airway.⁵⁰ Therefore, the level of NLR were gradually increased along with the aggravation of airflow limitation in patients with ACO. In this study, no correlation between EOS and FEV₁%pred was found in patients with ACO, which is attributed to the large proportion of patients with a history of ICS use in the included samples. ICS can reduce the FEV₁ decline in patients with higher blood eosinophils counts at baseline.⁵¹

Although many previous studies have demonstrated the value of inflammatory markers in ACO diagnosis,^15–19 the results remain highly controversial.²⁰ Kobayashi et al¹⁵ found that 156.2/mm³ was the best diagnostic cut-off level of EOS for ACO diagnosis, with the sensitivity and specificity being 49.5% and 83.8%, respectively. Deng et al¹⁹ reported that the optimal cut-off level of FeNO was 29.0 ppb, with 80.0% sensitivity and 73.0% specificity. Takayama et al¹⁸ demonstrated 21.0 ppb and 250 cells/mL as the optimal diagnostic cut-off levels of FeNO and EOS for differentiating ACO from COPD in overall patients, but among patients naive to ICS, the cut-off value of FeNO was 25.0 ppb with 60.6% sensitivity and 87.7% specificity. However, Goto et al²⁰ pointed out that FeNO alone was insufficient to discriminate ACO from COPD. Notably, the above studies had certain limitations. First, the diagnosis of ACO was not performed based on the accepted method, and some diseases that may affect the expression of inflammatory markers were not excluded. Second, some articles did not mention whether FeNO, lung function and blood test were completed on the same day. Third, patients with a history of ICS use and smoking were not excluded, and the diagnostic value of NLR in the two diseases has not been studied. In the present study, the definition in the GINA/GOLD joint document was used in ACO diagnosis, and all of the pulmonary function, blood and FeNO tests were performed on the same day, what’s more, some diseases that may affect the expression of inflammatory markers and the effects of ICS treatment and smoking history were excluded when evaluating the diagnostic value of inflammatory markers. Our results clearly showed that either FeNO or EOS has a high specificity in distinguishing ACO from COPD among patients without ICS use or patients with a smoking history alone, and the sensitivity for diagnosis can be improved to 91.7% when the two indexes are a combination of patients without a history of ICS use and smoking. However, there is no value in them in differentiating between ACO and COPD in patients with ICS and a smoking history. Since both ICS and smoking can affect FeNO and EOS levels,^22–24 and the diagnostic value of them may be weakened simultaneously. The cut-off value of FeNO for ACO diagnosis in this study were higher than those in previous studies, there are several potential reasons, as follows: first, this study was conducted in Asians, a meta-analysis showed that the FeNO value of Asians appears to be higher than Caucasians;⁵² second, Huang et al⁵³ found that FeNO measured by Sunvou device (used in this study) showed a higher value compared to FeNO measured by NIOX VERO (used in several previous studies^15,16,18,20); third, people exposed to higher levels of air pollutant, especially PM2.5, had a higher FeNO level.⁵⁴ Shaanxi Province was found to be the main exogenous source of total particulate matter in northwest China, and the PM2.5 concentrations of the provincial capital Xi’an mainly originates from local emissions.^55,56 Therefore, we consider it appropriate to further investigate the optimal cut-off value of FeNO and EOS for ACO diagnosis based on ethnic and regional groups.

In this study, we identified and assessed the values of inflammatory biomarkers in ACO diagnosis. Compared with previous studies, our research has some advantages. First, the diagnostic accuracy of FeNO, EOS and NLR in ACO was evaluated with the exclusion of confounding factors, including ICS use and smoking, and some diseases that may affect the expression of inflammatory markers were excluded in our study. Second, the diagnostic values of NLR and combination of FeNO and EOS were investigated, and the ACO patients in our study were screened according to the widely accepted criteria defined in the GINA/GOLD joint document, and all patients with ACO must meet the 3 main criteria of GesEPOC 2017 and a consensus definition of ACOS from a round table discussion, which guaranteed the accuracy of ACO diagnosis. Third, the inflammatory biomarkers were performed on the same day to guarantee the accuracy of the study, and we analyzed the differential value of NLR between the two diseases for the first time. Of course, our study may have some limitations. Selection bias might exist as the data were from the same hospital. Smokers have not been classified as current and ex-smoker groups for further analysis. The sample size was not large enough to support some results in the stratified analysis. Therefore, the results of this study need to be confirmed with data from multiple centers, with a larger sample size, and probably by prospective research.

Conclusion

Our results demonstrate that the inflammatory biomarkers FeNO and EOS can be used to support the diagnosis of ACO, especially in patients without a history of ICS use and smoking. However, there was no diagnostic value of them in patients with a history of smoking and ICS use.

Disclosure

The authors declared no conflicts of interest in this work.

Acknowledgment

Thanks to all the patients and researchers who participated in this study.